Change over period: —
NSE · LAURUSLABS
LAURUSLABS
-5.4% from the 52-week high · +149.7% above the low
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana and currently employs 5,753 full-time employees. The company went IPO on 2016-12-19. The firm offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The firm operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The firm operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The firm sell its APIs in 56 countries.
The short version. LAURUSLABS reported revenue of ₹2,206 crore for Sep 2026, up 33.5% from a year earlier. Net profit was ₹441 crore (up 126.2% year on year). Return on equity was 16.8% in Mar 2026. Promoter holding was 27.47% in Sep 2026, down 0.15 points over 8 quarters.
1 · The price
How has the stock traded?
LAURUSLABS trades 5.4% below its 52-week high and 149.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,206 cr.
Sep 2026 net profit of ₹441 cr.
8.2 pts higher than a year earlier.
Revenue compounded at 4.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2206 | 2026 | 1812 | 1778 | 1653 | 1570 | 1720 | 1415 |
| Net profit | 441 | 368 | 279 | 252 | 195 | 163 | 234 | 92 |
| Net margin % | 20.0 | 18.1 | 15.4 | 14.2 | 11.8 | 10.4 | 13.6 | 6.5 |
| EPS (₹) | 8.17 | 6.8 | 5.17 | 4.66 | 3.61 | 3.02 | 4.33 | 1.71 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6813 | 5554 | 5041 | 6041 | 4936 | 4814 | 2832 | 2292 |
| Net profit | 889 | 358 | 161 | 790 | 828 | 984 | 255 | 94 |
| Net margin % | 13.0 | 6.5 | 3.2 | 13.1 | 16.8 | 20.4 | 9.0 | 4.1 |
| EPS (₹) | 16.46 | 6.64 | 2.98 | 14.67 | 15.4 | 18.33 | 4.78 | 1.76 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 16.8% in Mar 2026; debt to equity is 0.45.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 16.8 | 8.0 | 3.9 | 19.6 |
| Return on capital % | 19.7 | 12.1 | 8.0 | 24.4 |
| EBITDA margin % | 26.7 | 20.1 | 15.9 | 26.4 |
| Net margin % | 12.9 | 6.4 | 3.2 | 13.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 4.3% | 7.3% |
| Profit CAGR | 4.0% | -2.0% |
4 · The owners
Who holds it, and are they adding?
Down 0.15 pts over 8 quarters.
Up 5.28 pts over 8 quarters.
Down 0.88 pts over 8 quarters.
+54 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 27.62 | 27.62 | 27.59 | 27.59 | 27.49 | 27.49 | 27.47 | 27.47 | -0.15 |
| FII | 25.56 | 25.52 | 25.7 | 26.16 | 26.52 | 25.82 | 28.0 | 30.84 | +5.28 |
| DII | 12.74 | 11.77 | 11.94 | 11.73 | 12.43 | 13.97 | 13.74 | 11.86 | -0.88 |
| Public | 34.08 | 35.09 | 34.77 | 34.51 | 33.56 | 32.71 | 30.78 | 29.83 | -4.25 |
Mutual fund holdings · Oct 2026
233 schemes hold this stock
179 the month before.
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND14.12% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund14.09% of NAV
- SAMCO LARGE & MID CAP FUND10.27% of NAV
- ICICI Prudential Nifty Pharma ETF9.27% of NAV
- Nippon India Nifty Pharma ETF9.26% of NAV
- ICICI Prudential Nifty Pharma Index Fund9.26% of NAV
- TATA NIFTY MIDCAP 150 MOMENTUM 50 INDEX FUND8.73% of NAV
- SBI Nifty Midcap 150 Momentum 50 ETF8.72% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for LAURUSLABS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about LAURUSLABS
What is the LAURUSLABS share price?
LAURUSLABS (LAURUSLABS) last closed at ₹2,306.00, down 0.71% on the day. Its 52-week range is ₹930.20 to ₹2,454.00.
What is the market cap of LAURUSLABS?
LAURUSLABS has a market capitalisation of about ₹125,461 crore. Its price-to-earnings ratio is 94.2.
How are LAURUSLABS's latest results?
LAURUSLABS reported revenue of ₹2,206 crore for Sep 2026, up 33.5% from a year earlier. Net profit was ₹441 crore (up 126.2% year on year). Return on equity was 16.8% in Mar 2026. Promoter holding was 27.47% in Sep 2026, down 0.15 points over 8 quarters.
Who owns LAURUSLABS?
As of Sep 2026, shareholding was: Promoter 27.47%, FII 30.84%, DII 11.86%, Public 29.83%.
How many mutual funds hold LAURUSLABS?
233 mutual fund schemes held LAURUSLABS in October 2026. That compares with 179 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 08 May 2026 · Interim Dividend - Rs. 1.2
- 31 Oct 2025 · Interim Dividend - Rs. 0.8
- 09 May 2025 · Interim Dividend - Rs. 0.8
- 06 Nov 2024 · Interim Dividend - Rs. 0.4
- 08 May 2024 · Interim Dividend - Rs. 0.4
- 02 Nov 2023 · Interim Dividend - Rs. 0.4
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.